Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Transfusion01:15

Blood Transfusion

452
Blood transfusion is a critical medical procedure that saves lives and treats various medical conditions. It involves transferring blood from a donor to a recipient. This process requires a thorough understanding of the ABO blood group system and its associated antigens and antibodies.
Blood Transfusion Overview
A blood transfusion is a medical procedure used to replace blood lost due to injury, surgery, or to treat conditions such as anemia or cancer. During a transfusion, donor blood is...
452
Blood Transfusion and Agglutination02:45

Blood Transfusion and Agglutination

10.7K
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
10.7K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

267
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
267
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

73
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
73
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

1.2K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.2K
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.0K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Abbreviated Dual Antiplatelet Therapy in Patients With High Bleeding Risk Undergoing PCI of Bifurcation Lesions: A Prespecified Substudy of the MASTER DAPT Trial.

Circulation. Cardiovascular interventions·2026
Same author

Reported safety events from ultrasound enhancing agents: a critical reappraisal.

Echo research and practice·2026
Same author

Paclitaxel-Coated Balloon Versus Uncoated Balloon for Coronary In-Stent Restenosis: Two-Year Follow-Up of the AGENT-IDE Randomized Clinical Trial.

Circulation·2026
Same author

Evaluating the Safety of Tranexamic Acid in Cancer Surgery: Clinical Evidence and Biological Rationale.

Transfusion medicine reviews·2026
Same author

Helping Underdeveloped Lungs with Cells (HULC-2): mesenchymal stromal cells in extreme preterm infants at risk of developing bronchopulmonary dysplasia - a study protocol of a phase 2 multicentre double blind randomised controlled trial in Canada.

BMJ open·2026
Same author

Reevaluating the Use of Race/Ethnicity in the MESA Risk Score.

Journal of the American Heart Association·2026

Related Experiment Video

Updated: May 20, 2025

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

19.3K

Blood Transfusion in Patients With Acute Myocardial Infarction, Anemia, and Heart Failure: Lessons From MINT.

Andrew M Goldsweig1,2,3, William J Kostis4, Brandon M Herbert5

  • 1Department of Cardiovascular Medicine, Baystate Medical Center (A.M.G.).

Circulation. Heart Failure
|March 26, 2025
PubMed
Summary

A liberal blood transfusion strategy is safe for patients with myocardial infarction (MI) and anemia, even those with heart failure (HF). Restrictive transfusion may lead to worse outcomes, especially in patients with pre-existing HF.

Keywords:
anemiaheart failurehemoglobinmyocardial infarction

More Related Videos

Intramyocardial Cell Delivery: Observations in Murine Hearts
08:12

Intramyocardial Cell Delivery: Observations in Murine Hearts

Published on: January 24, 2014

13.4K
A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
07:24

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy

1.7K

Related Experiment Videos

Last Updated: May 20, 2025

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

19.3K
Intramyocardial Cell Delivery: Observations in Murine Hearts
08:12

Intramyocardial Cell Delivery: Observations in Murine Hearts

Published on: January 24, 2014

13.4K
A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
07:24

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy

1.7K

Area of Science:

  • Cardiology
  • Transfusion Medicine
  • Critical Care Medicine

Background:

  • Blood transfusions can cause adverse events like heart failure (HF) in acute myocardial infarction (MI) patients.
  • This study examines transfusion strategies in MI patients with and without baseline HF.

Purpose of the Study:

  • To compare the effects of restrictive versus liberal transfusion strategies on patient outcomes.
  • To analyze outcomes based on the presence or absence of baseline heart failure in patients with MI and anemia.

Main Methods:

  • The Myocardial Ischemia and Transfusion (MINT) trial randomized 3504 MI patients with anemia (hemoglobin <10 g/dL) to restrictive (<8 g/dL) or liberal (<10 g/dL) transfusion.
  • Outcomes were compared between patients with and without baseline HF.

Main Results:

  • Patients with baseline HF had higher rates of death or HF (18.0%) compared to those without (10.0%).
  • Restrictive transfusion showed numerically higher rates of death or HF in patients with baseline HF.
  • Restrictive transfusion significantly reduced HF rates in patients without baseline HF (rate ratio, 0.51; Pinteraction=0.02).

Conclusions:

  • A liberal transfusion strategy is safe and recommended for MI patients with anemia, including those with HF.
  • Restrictive transfusion strategies may be associated with worse outcomes, particularly in patients with baseline HF.